1. |
Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis[J/OL]. Clin Immunol, 2020, 211: 108322[2019-12-09]. https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-016-0088-2. DOI: 10.1016/j.clim.2019.108322.
|
2. |
杨培增, 张震, 周红颜, 等. 葡萄膜炎致盲目特点及原因探讨[J]. 中华眼底病杂志, 2005, 21(6): 350-352. DOI: 10.3760/j.issn: 1005-1015.2005.06.002.Yang PZ, Zhang Z, Zhou HY, et al. Characteristics and reasons of blindness induced by uveitis[J]. Chin J Ocul Fundus Dis, 2005, 21(6): 350-352. DOI: 10.3760/j.issn: 1005-1015.2005.06.002.
|
3. |
郭春英, 杨柳. 102例少年儿童葡萄膜炎临床分析[J]. 中华眼底病杂志, 2010, 26(5): 414-417. DOI: 10.3760/cma.j.issn.1005-1015.2010.05.04.Guo CY, Yang L. Clinical analysis of pediatric uveitis in 102 children[J]. Chin J Ocul Fundus Dis, 2010, 26(5): 414-417. DOI: 10.3760/cma.j.issn.1005-1015.2010.05.04.
|
4. |
Gueudry J, Touhami S, Quartier P, et al. Therapeutic advances in juvenile idiopathic arthritis-associated uveitis[J]. Curr Opin Ophthalmol, 2019, 30(3): 179-186. DOI: 10.1097/ICU.0000000000000559.
|
5. |
郑曰忠, 时冀川. 葡萄膜炎的生物治疗进展[J]. 中华眼底病杂志, 2008, 24(5): 389-393.Zheng YZ, Shi JC. Progress in biotherapy of uveitis[J]. Chin J Ocul Fundus Dis, 2008, 24(5): 389-393.
|
6. |
Stroh IG, Moradi A, Burkholder BM, et al. Occurrence of and risk factors for ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis[J]. Ocul Immunol Inflamm, 2017, 25(4): 503-512. DOI: 10.3109/09273948.2016.1142573.
|
7. |
Sijssens KM, Rothova A, Van De Vijver DA, et al. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis[J]. Am J Ophthalmol, 2007, 144(4): 574-579. DOI: 10.1016/j.ajo.2007.06.030.
|
8. |
Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting[J/OL]. Pediatr Rheumatol Online J, 2018, 16(1): 46[2018-07-11]. https://pubmed.ncbi.nlm.nih.gov/29996864/. DOI: 10.1186/s12969-018-0255-8.
|
9. |
Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
|
10. |
Smith JR, Matthews JM, Conrad D, et al. Recommendations for the management of childhood juvenile idiopathic arthritis-type chronic anterior uveitis[J]. Clin Exp Ophthalmol, 2021, 49(1): 38-45. DOI: 10.1111/ceo.13856.
|
11. |
Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus[J]. Rheumatol Int, 2015, 35(5): 777-785. DOI: 10.1007/s00296-015-3231-3.
|
12. |
Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s)[J]. Microsc Res Tech, 2000, 50(3): 184-195. DOI: 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.
|
13. |
Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice[J]. Invest Ophthalmol Vis Sci, 1994, 35(11): 3884-3889.
|
14. |
Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming[J]. Invest Ophthalmol Vis Sci, 1996, 37(11): 2211-2218.
|
15. |
Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins[J]. Prog Retin Eye Res, 2010, 29(6): 610-621. DOI: 10.1016/j.preteyeres.2010.08.003.
|
16. |
Kociok N, Heppekausen H, Schraermeyer U, et al. The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells[J]. Exp Eye Res, 1998, 67(2): 237-250. DOI: 10.1006/exer.1998.0517.
|
17. |
Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis[J]. Surv Ophthalmol, 2015, 60(6): 575-589. DOI: 10.1016/j.survophthal.2015.06.004.
|
18. |
Bhatt N, Tucker W, Sen HN, et al. Biologic therapies: anti-tumor necrosis factor-α, anti-interleukins, rituximab and others[J]. Dev Ophthalmol, 2016, 55: 252-264. DOI: 10.1159/000431201.
|
19. |
赵潺. 解读SHARE倡议和ACR/AF关于JIA相关葡萄膜炎的最新治疗共识[J]. 中国斜视与小儿眼科杂志, 2019, 27(3): 1-4. DOI: 10.3969/J.ISSN.1005-328X.2019.03.001.Zhao C. Interpretation of recent consensus recommendations developed recently by the SHARE initiative and the American College of Rheumatology/Arthritis Foudation[J]. Chinese Journal of Strabismus Pediatric Ophthalmology, 2019, 27(3): 1-4. DOI: 10.3969/J.ISSN.1005-328X.2019.03.001.
|
20. |
Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716. DOI: 10.1002/acr.23871.
|
21. |
Henderson LA, Zurakowski D, Angeles-Han ST, et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry[J/OL]. Pediatr Rheumatol Online J, 2016, 14(1): 9[2016-02-16]. https://pubmed.ncbi.nlm.nih.gov/26879972/. DOI: 10.1186/s12969-016-0069-5.
|
22. |
Yasumura J, Yashiro M, Okamoto N, et al. Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ)[J/OL]. Pediatr Rheumatol Online J, 2019, 17(1): 15[2019-04-11]. https://pubmed.ncbi.nlm.nih.gov/30975163/. DOI: 10.1186/s12969-019-0318-5.
|
23. |
Cheung CSY, Mireskandari K, Ali A, et al. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis[J]. Br J Ophthalmol, 2020, 104(7): 938-942. DOI: 10.1136/bjophthalmol-2019-314875.
|
24. |
Simonini G, Bracaglia C, Cattalini M, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis[J]. J Rheumatol, 2017, 44(6): 822-826. DOI: 10.3899/jrheum.161336.
|
25. |
Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003-1011. DOI: 10.1136/annrheumdis-2017-212089.
|
26. |
Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J]. N Engl J Med, 2017, 376(17): 1637-1646. DOI: 10.1056/NEJMoa1614160.
|
27. |
Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT[J]. Health Technol Assess, 2019, 23(15): 1-140. DOI: 10.3310/hta23150.
|
28. |
Ramanan AV, Guly C. Adalimumab for childhood onset uveitis[J]. Ann Rheum Dis, 2018, 77(7): 961-962. DOI: 10.1136/annrheumdis-2017-212767.
|
29. |
Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
|
30. |
Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
|
31. |
Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2018, 45(8): 1167-1172. DOI: 10.3899/jrheum.171006.
|
32. |
Jari M, Shiari R, Salehpour O, et al. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis[J/OL]. Orphanet J Rare Dis, 2020, 15(1): 41[2020-02-04]. https://pubmed.ncbi.nlm.nih.gov/32019589/. DOI: 10.1186/s13023-020-1324-x.
|
33. |
Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis[J]. Arthritis Rheum, 2005, 53(1): 18-23. DOI: 10.1002/art.20904.
|
34. |
Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review[J]. Clin Exp Rheumatol, 2018, 36(4): 652-657.
|
35. |
Ormaechea MS, Hassan M, Onghanseng N, et al. Safety of systemic therapy for noninfectious uveitis[J]. Expert Opin Drug Saf, 2019, 18(12): 1219-1235. DOI: 10.1080/14740338.2019.1692810.
|
36. |
Simonini G, Ferrara G, Pontikaki I, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration[J]. Arthritis Care Res (Hoboken), 2018, 70(7): 1046-1051. DOI: 10.1002/acr.23435.
|
37. |
Acharya NR, Patel S, Homayounfar G, et al. Relapse of juvenile idiopathic arthritis-associated uveitis after discontinuation of immunomodulatory therapy[J]. Ocul Immunol Inflamm, 2019, 27(4): 686-692. DOI: 10.1080/09273948.2018.1424341.
|
38. |
Horton S, Jones AP, Guly CM, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial[J]. Am J Ophthalmol, 2019, 207: 170-174. DOI: 10.1016/j.ajo.2019.06.007.
|
39. |
Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious paediatric uveitis in the era of biologic therapy[J/OL]. Pediatr Rheumatol Online J, 2018, 16(1): 51[2018-08-06]. https://pubmed.ncbi.nlm.nih.gov/30081917/. DOI: 10.1186/s12969-018-0266-5.
|
40. |
Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis[J]. Surv Ophthalmol, 2016, 61(2): 197-210. DOI: 10.1016/j.survophthal.2015.10.005.
|
41. |
Grajewski RS, Zurek-Imhoff B, Roesel M, et al. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis[J]. Acta Ophthalmol, 2012, 90(7): 657-662. DOI: 10.1111/j.1755-3768.2011.02110.x.
|
42. |
Kulik U, Wiklund A, Kugelberg M, et al. Long-term results after primary intraocular lens implantation in children with juvenile idiopathic arthritis-associated uveitis[J]. Eur J Ophthalmol, 2019, 29(5): 494-498. DOI: 10.1177/1120672118799623.
|
43. |
Sijssens KM, Los LI, Rothova A, et al. Long-term ocular complications in aphakic versus pseudophakic eyes of children with juvenile idiopathic arthritis-associated uveitis[J]. Br J Ophthalmol, 2010, 94(9): 1145-1149. DOI: 10.1136/bjo.2009.167379.
|
44. |
Magli A, Forte R, Rombetto L, et al. Cataract management in juvenile idiopathic arthritis: simultaneous versus secondary intraocular lens implantation[J]. Ocul Immunol Inflamm, 2014, 22(2): 133-137. DOI: 10.3109/09273948.2013.834062.
|
45. |
Kesav N, Palestine AG, Kahook MY, et al. Current management of uveitis-associated ocular hypertension and glaucoma[J]. Surv Ophthalmol, 2020, 65(4): 397-407. DOI: 10.1016/j.survophthal.2019.12.003.
|
46. |
Leinonen S, Kotaniemi K, Kivelä T, et al. Potential effect of tumor necrosis factor inhibitors on trabeculectomy with mitomycin C for patients with juvenile idiopathic arthritis-related uveitic glaucoma: a retrospective analysis[J]. JAMA Ophthalmol, 2015, 133(11): 1323-1328. DOI: 10.1001/jamaophthalmol.2015.3387.
|
47. |
de Boer J, Steijaert A, van den Bor R, et al. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis[J]. Ocul Immunol Inflamm, 2015, 23(1): 67-73. DOI: 10.3109/09273948.2013.871566.
|
48. |
Interlandi E, Latanza L, Pellegrini F, et al. Regression of unusual optic disk neovascularization after adalimumab in a case of juvenile idiopathic arthritis-related uveitis[J]. J AAPOS, 2017, 21(5): 412-414. DOI: 10.1016/j.jaapos.2017.05.028.
|